Get the Stockscreener App
16.46
5.04%
0.79
Pre-market:
16.68
0.22
+1.34%
Xencor Inc stock is traded at $16.46, with a volume of 1.15M.
It is up +5.04% in the last 24 hours and up +44.26% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$15.67
Open:
$15.47
24h Volume:
1.15M
Relative Volume:
1.41
Market Cap:
$1.22B
Revenue:
$97.36M
Net Income/Loss:
$-172.42M
P/E Ratio:
-7.1615
EPS:
-2.2984
Net Cash Flow:
$-188.84M
1W Performance:
+7.02%
1M Performance:
+44.26%
6M Performance:
+16.00%
1Y Performance:
+99.03%
1-Day Range:
$15.36
$16.51
1-Week Range:
$14.61
$16.51
52-Week Range:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
16.46 | 1.22B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
498.43 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.88 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.30 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.50 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.77 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Form 4 Xencor Inc For: 8 July By Investing.com - Investing.com Nigeria
Ellen Feigal at Xencor (XNCR) receives RSUs and options equity awards - Stock Titan
Xencor (XNCR) awards RSUs and stock options to director Gorman - Stock Titan
Xencor (XNCR) director Kurt Gustafson granted RSUs and stock options - Stock Titan
[Form 4] Xencor Inc Insider Trading Activity - Stock Titan
Xencor (XNCR) director granted RSUs and stock options in equity award - Stock Titan
Xencor (XNCR) director granted RSUs and 20,604 stock options at $12.20 - Stock Titan
Xencor (NASDAQ: XNCR) director receives new RSU and stock option grant - Stock Titan
XENCOR Maintains Buy Rating -- Price Target Lowered to $27.00 by Truist Securities - GuruFocus
XNCRXencor Inc Revenue Breakdown - Finviz
Enterprise value to revenue forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to earnings forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to sales forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to sales forward of Xencor, Inc. – TRADEGATE:XE9 - TradingView
Liquidity Mapping Around (XNCR) Price Events - Stock Traders Daily
XE9 Forecast — Price Target — Prediction for 2027 - TradingView
Xencor, Inc. Actuals & Estimates (FWB:XE9) - TradingView
XNCR Forecast — Price Target — Prediction for 2027 - TradingView
Xencor, Inc. Actuals & Estimates (NASDAQ:XNCR) - TradingView
Price to book forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xencor director Ellen Feigal sells $89,369 in company stock By Investing.com - Investing.com South Africa
Insider Sell Alert: Ellen Feigal Sells Shares of Xencor Inc (XNC - GuruFocus
Form 4 Xencor Inc For: 22 June By Investing.com - Investing.com Nigeria
Xencor director Ellen Feigal sells $89,369 in company stock - Investing.com
Xencor (XNCR) director’s 10b5-1 sale covers 6,843 common shares - Stock Titan
XNCR Q1 2026 Earnings: Deep Loss Miss Weighs on SentimentProfit Warning Alert - dars.gov.et
Xencor, Inc. Files 8-K: Company Details, Stock Info, and Executive Plan Updates for 2026 - Minichart
Xencor Shareholders Approve Directors, Incentive Plan Amendments - TipRanks
Why (XNCR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Xencor (NASDAQ: XNCR) investors back 4M-share equity plan boost and all proposals - Stock Titan
Xencor Inc (XNCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
[144] Xencor Inc SEC Filing - Stock Titan
Insider Sell Alert: Richard Ranieri Sells Shares of Xencor Inc (XNCR) - GuruFocus
Xencor Inc (XNCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xencor Inc (XNCR) Institutional Confidence - TradingKey
Xencor Inc (XNCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xencor Inc (XNCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xencor Inc (XNCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xencor Inc (XNCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xencor Inc (XNCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Director at Xencor (XNCR) sells 7,527 shares under 10b5-1 plan - Stock Titan
Xencor (XNCR) director sells 5,474 shares under Rule 10b5-1 plan - Stock Titan
Xencor (XNCR) director Ranieri sells 5,474 shares under 10b5-1 plan - Stock Titan
Planned share sale by Xencor (XNCR) director under Rule 10b5-1 plan - Stock Titan
Barclays Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution - Yahoo Finance
Xencor Inc Stock (US98401F1057): Analyst Views In Focus After Recent Collaboration Momentum - AD HOC NEWS
Understanding Momentum Shifts in (XNCR) - Stock Traders Daily
Xencor (XNCR) Slides 2% as Biotech Sentiment Weakens — Support TestedTRIN Signal - newsline.com
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial - MSN
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.27%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):